Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Abilify - withdrawal of application for variation to marketing authorisation

Abilify - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

aripiprazole
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Abilify
  • More information on Abilify

Overview

On 17 November 2009, Otsuka Pharmaceutical Europe Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Abilify, in the treatment of resistant major depressive episodes.

Abilify is a medicine that contains the active substance aripiprazole. It is available as tablets, orodispersible tablets (tablets that dissolve in the mouth), an oral solution and a solution for injection.

Abilify has been authorised since June 2004. It is already used to treat schizophrenia, and to treat and prevent manic episodes (periods of extremely high mood) in patients with bipolar I disorder.

Abilify was also expected to be used, in addition to antidepressants, to treat major depressive episodes in patients who had not responded adequately to previous antidepressant treatment. Major depressive episodes are periods of depressed mood or loss of interest in everyday activities that last for at least two weeks in patients with major depression.

The active substance in Abilify, aripiprazole, is an antipsychotic medicine. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. Aripiprazole is thought to act mainly by being a 'partial agonist' for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin). This means that aripiprazole acts like dopamine and 5-hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters. Since dopamine and 5-hydroxytryptamine are involved in major depression, Abilify is expected to help to normalise the activity of the brain when it is added to antidepressants, reducing the symptoms of major depressive episodes.

The company presented the results of three short-term and one long-term study to support its application.

The short-term studies involved patients with major depressive episodes that had not responded to up to three previous antidepressant treatments. At the start of the study, the patients were put on an eight-week course of an antidepressant (escitalopram, sertraline, venlafaxine, fluoxetine or paroxetine). Each patient received an antidepressant that they had not previously taken for the current depressive episode. The 1,090 patients who did not respond to this antidepressant then added either Abilify or placebo (a dummy treatment). The main measure of effectiveness was the change in symptoms over the six weeks of dual treatment. The short-term studies were 'double-blind', which means that neither the patients nor the investigators knew which patients were receiving Abilify and which were receiving placebo.

The long-term study looked at the maintenance of Abilify's effects when added to an antidepressant. The study lasted up to a year and involved 1,076 patients, some of whom had completed one of the three short-term studies. Abilify was not compared with any other treatments in this study and the patients knew which medicines they were taking.

The evaluation was withdrawn after 'day 90'. This means that the CHMP had evaluated the documentation provided by the company and formulated lists of questions. After the CHMP had assessed the company's responses to the questions, there were still some unresolved issues.

Based on the review of the data and the company's responses to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Abilify could not have been approved for the treatment of resistant major depressive episodes.

The CHMP was concerned over the patients included in the studies, as it was not clear whether they all had resistant depression, defined as failure to respond to at least two previous antidepressants. The Committee was also concerned that there was no long-term information from 'double-blind' studies looking at the maintenance of Abilify's effects and its ability to prevent depression coming back. Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Abilify in the treatment of major depressive episodes did not outweigh its risks.

The letter from the company notifying the CHMP of the withdrawal of the application is available below.

The company informed the CHMP that there are no consequences for patients currently in clinical trials or compassionate use programmes using Abilify. If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.

There are no consequences on the use of Abilify in its authorised indications, for which the balance of benefits and risks remains unchanged.

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Abilify (aripiprazole)

Reference Number: EMA/809491/2009

English (EN) (68.66 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View
Other languages (21)

български (BG) (154.35 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

español (ES) (124.68 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

čeština (CS) (163.25 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

dansk (DA) (117.21 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Deutsch (DE) (119.43 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

eesti keel (ET) (114.47 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

ελληνικά (EL) (176.12 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

français (FR) (116.7 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

italiano (IT) (110.95 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

latviešu valoda (LV) (143.88 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

lietuvių kalba (LT) (141.64 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

magyar (HU) (134.95 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Malti (MT) (142.36 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Nederlands (NL) (115.74 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

polski (PL) (143.63 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

português (PT) (117.18 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

română (RO) (140.88 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

slovenčina (SK) (159.27 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

slovenščina (SL) (137.66 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Suomi (FI) (114.31 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

svenska (SV) (133.85 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Key facts

Name of medicine
Abilify
EMA product number
EMEA/H/C/000471
Active substance
aripiprazole
International non-proprietary name (INN) or common name
aripiprazole
Therapeutic area (MeSH)
  • Schizophrenia
  • Bipolar Disorder
Anatomical therapeutical chemical (ATC) code
N05AX12
Marketing authorisation holder
Otsuka Pharmaceutical Netherlands B.V.
Date of issue of marketing authorisation valid throughout the European Union
04/06/2004
Date of withdrawal
17/11/2009

Documents

Withdrawal assessment report for Abilify

AdoptedReference Number: EMA/CHMP/820673/2009

English (EN) (321.64 KB - PDF)

First published: 24/02/2010Last updated: 24/02/2010
View

Withdrawal letter : Abilify

English (EN) (51.34 KB - PDF)

First published: 05/01/2010Last updated: 05/01/2010
View

Otsuka Pharmaceutical Europe Ltd withdraws its application for an extension of indication for Abilify (aripiprazole)

Reference Number: EMEA/749487/2009

English (EN) (25 KB - PDF)

First published: 19/11/2009Last updated: 19/11/2009
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Abilify

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)
21/09/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012
14/12/2012
Otsuka Pharmaceutical Europe Ltd withdraws its application for an extension of indication for Abilify (aripiprazole)
19/11/2009

More information on Abilify

  • Abilify
This page was last updated on 19/11/2009

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union